REGN

The market expects Regeneron (REGN) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates. The earnings report, which is expected to be released on October 30, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower. While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise. This biopharmaceutical company is expected to post quarterly earnings of $16.08 per share in its upcoming report, which represents a year-over-year change of +35.9%. Revenues are expected to be $4.55 billion, up 21.2% from the year-ago quarter. The consensus EPS estimate for the quarter has been revised 36.31% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts. Price, Consensus and EPS Surprise Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction). The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only. A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP. Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell). For Regeneron, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -1.12%. On the other hand, the stock currently carries a Zacks Rank of #3. So, this combination makes it difficult to conclusively predict that Regeneron will beat the consensus EPS estimate. Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number. For the last reported quarter, it was expected that Regeneron would post earnings of $10 per share when it actually produced earnings of $14.29, delivering a surprise of +42.90%. Over the last four quarters, the company has beaten consensus EPS estimates four times. An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss. That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. Regeneron doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release. Another stock from the Zacks Medical - Biomedical and Genetics industry, LENZ Therapeutics, Inc. (LENZ), is soon expected to post loss of $0.99 per share for the quarter ended September 2026. This estimate indicates a year-over-year change of -67.8%. Revenues for the quarter are expected to be $4.01 million, down 67.9% from the year-ago quarter. The consensus EPS estimate for LENZ Therapeutics, Inc. has been revised 2.2% higher over the last 30 days to the current level. However, a higher Most Accurate Estimate has resulted in an Earnings ESP of +2.79%. This Earnings ESP, combined with its Zacks Rank #3 (Hold), suggests that LENZ Therapeutics, Inc. will most likely beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates two times. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report LENZ Therapeutics, Inc. (LENZ) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Longleaf Partners, managed by Southeastern Asset Management, released its third-quarter 2026 investor letter for its "Partners Fund". The letter can be downloaded here. Coming into this year, the Fund's three-year annualized returns were at 11.7%, but recent performance, particularly this year and in Q3, has raised concerns about the investment strategy. The Fund returned 2.41% in Q3 and -3.15% YTD compared to 2.30% and 12.75% for the S&P 500, respectively. Despite varying stock prices, the firm believes that it is on the right track, as company values perform better than stock prices. Macro factors, including higher interest rates, impact the market, but financially strong investments are expected to endure. Although some stocks have seen earnings disappointment, long-term values remain intact. Groups within the portfolio experience disconnects between earnings growth and stock performance, with a combined outlook reflecting mid-single-digit growth potential. The portfolios' earnings multiples have decreased, presenting opportunities despite current frustrations. The firm remains optimistic about future returns and continues to improve value propositions. In addition, please check the Fund's top five holdings to know its best picks in 2026. In its Q3 2026 investor letter, RS Large Cap Value Strategy highlighted Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) as a notable contributor. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biotechnology company that develops and commercializes medicines to treat various diseases. On October 16, 2026, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) closed at $810.31 per share, reflecting a market capitalization of $83.43 billion. Over the past month, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) declined 1.64%, while its shares gained 36.12% over the past 52 weeks. RS Large Cap Value Strategy stated the following regarding Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in its Q3 2026 investor letter: "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) – Biopharma company Regeneron reported a solid set of results, with key drug Dupixent continuing to outpace our and the market's growth expectations. We were encouraged to see the company report that it leaned harder into share repurchase in the second quarter when its stock price was even more deeply discounted. The stock likely reacted well to expectations of a reset deal with partner Sanofi on Dupixent. This occurred after quarter end and was accretive to our value per share." Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. According to our database, 63 hedge fund portfolios held Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) at the end of the second quarter, down from 72 in the previous quarter. While we acknowledge the potential of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we discussed Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and shared a list of best-performing stocks in 2026 according to Claude AI. In addition, please check out our hedge fund investor letters Q3 2026 page for more investor letters from hedge funds and other leading investors. READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years. This article is originally published at Insider Monkey.

- Regeneron Pharmaceuticals reported Q2 revenue of US$4.29b, up 16.7% year on year, alongside positive 84 week Phase 3 OPTIMA data for Pasatru in adults with fibrodysplasia ossificans progressiva. The data supports its recently approved use in reducing new heterotopic ossification lesions and flare ups. - The 84 week OPTIMA readout suggests a sustained effect in limiting new rogue bone formation and flare ups while maintaining a generally consistent safety profile. This could reinforce Regeneron's rare disease franchise alongside an already broad late stage portfolio in oncology and immunology. - We will now look at how Regeneron's Q2 results and extended Pasatru data may influence its longer term investment narrative. Scan how Regeneron Pharmaceuticals compares with other biotech stocks riding similar momentum by reviewing our hand picked list of 20 high quality undiscovered gems in the sector. To stay in Regeneron Pharmaceuticals, you need to believe the core franchises like Dupixent and EYLEA HD can keep carrying most of the load while newer launches gradually matter more. The near term story is about translating Q2 revenue of US$15.5b over the last year and solid Q2 momentum into consistent execution rather than one off beats. The key short term catalyst is how effectively Regeneron converts its late stage and newly approved drugs such as Pasatru into dependable revenue streams as EYLEA faces rivalry and pricing pressure. The biggest current risk is retinal competition and potential erosion in EYLEA HD volumes and pricing, which the latest Pasatru data does not directly offset. The extended 84 week OPTIMA results for Pasatru look most relevant for the current narrative. Regeneron Pharmaceuticals now has longer term data backing sustained control of heterotopic ossification lesions and flare ups in adult FOP, with a safety profile that stayed generally consistent out to week 84 and no infection related discontinuations. For investors, that readout matters less as an immediate profit driver and more as proof the rare disease platform can move from approval to durable clinical performance. It supports the idea that future launches from the broader pipeline in oncology, immunology and obesity may also transition into longer running therapies if they clear trials and approvals. Regeneron Pharmaceuticals is currently tied to a forecast that points to revenues of US$20.5b and earnings of US$6.5b by 2029, based on analysts assuming 9.7% yearly revenue growth and an earnings increase of about US$2.2b from US$4.3b today. Uncover why Regeneron Pharmaceuticals' fair value indicates a 7% potential upside to its current price that could narrow quickly. Some of the lowest ranked analysts focus on legal risk around the fianlimab and Libtayo melanoma lawsuits rather than Pasatru. They already worked with a 2029 earnings figure closer to US$5.6b and about 6.0% annual revenue growth. That creates a far more cautious Regeneron Pharmaceuticals story that could shift as fresh FOP data is absorbed. Explore 4 other Regeneron Pharmaceuticals fair value estimates, including one that suggests it could be worth just $841.59. Don't just follow the ticker; dig into the data and build a conviction that's truly your own. - A great starting point for your Regeneron Pharmaceuticals research is our analysis highlighting 2 key rewards that could impact your investment decision. - See our latest analysis for Regeneron Pharmaceuticals. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Regeneron Pharmaceuticals' overall financial health at a glance. If the Regeneron Pharmaceuticals story has sharpened your thinking but you want a broader watchlist, the Simply Wall St Screener can help you hunt for other stocks that match your risk profile and income goals. - If capital preservation sits high on your list, start with a basket of 32 resilient stocks with low risk scores that score well on stability and downside resilience. - For investors hunting for quality at a reasonable entry point, scan through 33 high quality undervalued stocks that pair fundamentals with what our model flags as compressed pricing. - If income is the priority, focus on 8 dividend fortresses that combine higher yields with an emphasis on durability of payouts. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include REGN. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases. Valued at $80.1 billion by market cap, the company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Evkeeza, Libtayo, Inmazeb, Arcalyst, and Zaltrap. The biotechnology company is expected to announce its fiscal third-quarter earnings for 2026 before the market opens on Friday, Oct. 30. Ahead of the event, analysts expect Regeneron Pharmaceuticals to report a profit of $13.58 per share on a diluted basis, up 41% from $9.63 per share in the year-ago quarter. The company has consistently surpassed Wall Street's EPS estimates in its last four quarterly reports. - Dear Intel Fans, Mark Your Calendars for October 29 - Bill Gates Says Despite Elon Musk Being Mean to Him, He's Still 'In Awe' of His Work — 'He's Brilliant, He's Rich, He's Influential' - At 97, Charlie Munger Borrowed $37 Million to Go All-In on Alibaba — 2 Years Later He Called It One of the 'Worst Mistakes' of His Life - Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! For the full year, analysts expect Regeneron Pharmaceuticals to report EPS of $47.93, up 35% from $35.51 in fiscal 2025. Its EPS is expected to rise 10.4% year over year to $52.91 in fiscal 2027. REGN stock has outperformed the S&P 500 Index's ($SPX) 16.2% gains over the past 52 weeks, with shares up 35.9% during this period. Similarly, it outperformed the State Street Health Care Select Sector SPDR ETF's (XLV) 22.2% returns over the same time frame. REGN's outperformance has been largely driven by robust commercial momentum across key product lines, led by Dupixent, EYLEA HD, and Libtayo, which propelled the company to record sales highs. Dupixent served as a standout performer, with global sales surging near 38% to a record $6 billion and providing a substantial lift to REGN's collaboration income. Furthermore, the company strengthened its financial profile by fully repaying the Sanofi (SNY) Development Balance, effectively removing a long-standing profit drag. Concurrently, continuous advancements in its clinical pipeline, highlighted by regulatory review acceptances in the U.S. and Europe for cemdisiran in generalized myasthenia gravis, have reinforced investor confidence in its multi-year growth trajectory. Analysts' consensus opinion on REGN stock is moderately bullish, with a "Moderate Buy" rating overall. Out of 29 analysts covering the stock, 18 advise a "Strong Buy" rating, two suggest a "Moderate Buy," and nine give a "Hold." REGN's average analyst price target is $862.21, indicating a potential upside of 10.8% from the current levels. On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com

Regeneron Pharmaceuticals (REGN) shares have been in focus after the company reported quarterly revenue of US$4.29b, up 16.7% year on year. The results beat analyst expectations and have lifted the stock about 12.4% since the release. Regeneron Pharmaceuticals has been in a strong upswing, with a 7-day share price return of 7.68% and a 90-day share price return of 17.68%. The 1-year total shareholder return of 40.63% reflects momentum that has built over time as new drug data, expanded collaborations with Sanofi, and fresh oncology and obesity trial readouts have kept attention on the pipeline alongside the latest quarterly beat. Scan the momentum of Regeneron Pharmaceuticals against other biotech players by zeroing in on 20 high quality undiscovered gems that could be building similar pipelines away from the spotlight. The share price jump has pushed Regeneron Pharmaceuticals closer to analyst targets, yet a wide gap still appears between the current price and some fair value estimates. It raises the question of how much of that spread still points to upside valuation and how much already reflects pipeline optimism. Against a last close of $796.34, the most followed narrative points to a fair value of about $850.88. This frames recent strength in Regeneron Pharmaceuticals shares as still leaving some valuation headroom tied to its pipeline and Sanofi partnership. Regeneron Pharmaceuticals is still advancing a broad late stage pipeline in areas such as immunology, oncology, genetic medicines, and obesity. Continued readouts and regulatory decisions on these programs can add new revenue streams that support earnings growth beyond the current product portfolio. See why 86 investors see Regeneron Pharmaceuticals as 6% undervalued. Result: Fair Value of $850.88 (UNDERVALUED) Still, the Regeneron Pharmaceuticals story can change quickly if Kodiak Sciences' Zenkuda gains share against EYLEA HD, or if litigation around Libtayo and fianlimab escalates. Find out about the key risks to this Regeneron Pharmaceuticals narrative. Positive sentiment around Regeneron Pharmaceuticals is clear in the recent narrative, so consider acting promptly, test the assumptions, and weigh the trade offs yourself. To see how those strengths line up in the data, take a closer look at the 2 key rewards. If you only stop at Regeneron Pharmaceuticals, you risk missing other opportunities that might suit your goals or risk tolerance even better. - Target resilient balance sheets and steady fundamentals by scanning the list of solid balance sheet and fundamentals (25 results), which regularly clear strict financial health checks. - Hunt for quality at a discount by reviewing the 32 high quality undervalued stocks, which pair solid cash flows with prices that still look reasonable. - Build a foundation of stability by focusing on the 32 resilient stocks with low risk scores, which score well on volatility and financial risk metrics. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include REGN. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

As the Q2 earnings season wraps, let's dig into this quarter's best and worst performers in the biotechnology industry, including Regeneron (NASDAQ:REGN) and its peers. The biotechnology industry is defined by its high-risk, high-reward business model, as companies invest heavily in research and development to create innovative therapies and treatments. Breakthroughs can lead to transformative, patent-protected revenue streams. Companies in this space are also increasingly relying on AI and data to maximize the speed and efficiency of drug discovery. On the other hand the lengthy and expensive process of clinical trials and regulatory approval makes profitability uncertain and timelines unpredictable. The 14 biotechnology stocks we track reported a very strong Q2. As a group, revenues beat analysts' consensus estimates by 8.9%. Luckily, biotechnology stocks have performed well with share prices up 33.5% on average since the latest earnings results. Founded by scientists who wanted to build a company where science could thrive, Regeneron Pharmaceuticals (NASDAQ:REGN) develops and commercializes medicines for serious diseases, with key products treating eye conditions, allergic diseases, cancer, and other disorders. Regeneron reported revenues of $4.29 billion, up 16.7% year on year. This print exceeded analysts' expectations by 12.4%. Overall, it was an incredible quarter for the company with a beat of analysts' EPS estimates. Interestingly, the stock is up 12.4% since reporting and currently trades at $781.75. Is now the time to buy Regeneron? Access our full analysis of the earnings results here, it's free. Founded in 1978 and pioneering treatments for some of medicine's most complex challenges, Biogen (NASDAQ:BIIB) develops and markets therapies for neurological conditions, including multiple sclerosis, Alzheimer's disease, spinal muscular atrophy, and rare diseases. Biogen reported revenues of $2.74 billion, up 3.4% year on year, outperforming analysts' expectations by 12.1%. The business had an incredible quarter with a beat of analysts' EPS estimates and a solid beat of analysts' full-year EPS guidance estimates. The market seems happy with the results as the stock is up 14.3% since reporting. It currently trades at $235. Is now the time to buy Biogen? Access our full analysis of the earnings results here, it's free. Founded in 1991 as one of the pioneers in translating genetic discoveries into clinical applications, Myriad Genetics (NASDAQ:MYGN) develops genetic tests that assess disease risk, guide treatment decisions, and provide insights across oncology, women's health, and mental health. Myriad Genetics reported revenues of $190.7 million, down 10.5% year on year, falling short of analysts' expectations by 8.2%. It was a disappointing quarter as it posted full-year revenue guidance missing analysts' expectations significantly and a significant miss of analysts' EPS estimates. Myriad Genetics delivered the weakest performance against analyst estimates and weakest full-year guidance update in the group. As expected, the stock is down 22.4% since the results and currently trades at $4.17. Read our full analysis of Myriad Genetics's results here. Founded in 1980 during the early days of the biotechnology revolution, Amgen (NASDAQ:AMGN) is a biotechnology company that discovers, develops, and manufactures innovative medicines to treat serious illnesses like cancer, osteoporosis, and autoimmune diseases. Amgen reported revenues of $10.05 billion, up 9.5% year on year. This number beat analysts' expectations by 6.9%. Overall, it was an exceptional quarter as it also produced full-year revenue guidance exceeding analysts' expectations and an impressive beat of analysts' full-year EPS guidance estimates. The stock is up 10% since reporting and currently trades at $429.03. Read our full, actionable report on Amgen here, it's free. Founded in 2003 as Gene Security Network before rebranding in 2012, Natera (NASDAQ:NTRA) develops and commercializes genetic tests for prenatal screening, cancer detection, and organ transplant monitoring using its proprietary cell-free DNA technology. Natera reported revenues of $752.8 million, up 37.7% year on year. This print topped analysts' expectations by 13.6%. It was a stunning quarter as it also put up full-year revenue guidance exceeding analysts' expectations and a beat of analysts' EPS estimates. The stock is up 47.5% since reporting and currently trades at $391.37. Read our full, actionable report on Natera here, it's free. Over the past year, investors have been forced to repeatedly answer the same question: what is the market's biggest risk? The answer has changed several times, and each shift has reshaped market leadership. Late in 2025 and early 2026, artificial intelligence became the market's primary uncertainty. Investors questioned whether AI would erode software pricing power and weaken competitive moats as AI made it easier to replicate once-differentiated products. By the spring, technology took a back seat to geopolitics. The U.S. conflict with Iran briefly became the market's dominant narrative, raising concerns about oil prices, inflation, and global growth. But as energy markets remained orderly and fears of a prolonged supply disruption faded, investors quickly turned their focus back to fundamentals. Want to invest in winners with rock-solid fundamentals? Check out our Top 5 Quality Compounder Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Regeneron (REGN), which belongs to the Zacks Medical - Biomedical and Genetics industry. This biopharmaceutical company has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 27.03%. For the last reported quarter, Regeneron came out with earnings of $14.29 per share versus the Zacks Consensus Estimate of $10 per share, representing a surprise of 42.90%. For the previous quarter, the company was expected to post earnings of $8.52 per share and it actually produced earnings of $9.47 per share, delivering a surprise of 11.15%. For Regeneron, estimates have been trending higher, thanks in part to this earnings surprise history. And when you look at the stock's positive Zacks Earnings ESP (Expected Surprise Prediction), it's a great indicator of a future earnings beat, especially when combined with its solid Zacks Rank. Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Regeneron currently has an Earnings ESP of +1.21%, which suggests that analysts have recently become bullish on the company's earnings prospects. This positive Earnings ESP when combined with the stock's Zacks Rank #3 (Hold) indicates that another beat is possibly around the corner. We expect the company's next earnings report to be released on October 30, 2026. With the Earnings ESP metric, it's important to note that a negative value reduces its predictive power; however, a negative Earnings ESP does not indicate an earnings miss. Many companies end up beating the consensus EPS estimate, though this is not the only reason why their shares gain. Additionally, some stocks may remain stable even if they end up missing the consensus estimate. Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Clinical-stage biopharmaceutical company Kodiak Sciences (KOD) saw its shares jump 178% intraday on Sept. 28, after the company reported stellar results for its primary endpoint in the pivotal Phase 3 DAYBREAK trial in wet AMD for its flagship Zenkuda product, as well as its KSI-501 candidate. Zenkuda is an investigational anti-VEGF eye injection to treat serious retinal vascular diseases. Zenkuda's endpoint results are notable because they matched or exceeded those of Aflibercept, marketed as Eylea by Regeneron Pharmaceuticals (REGN). The results also show what clinical profile retina specialists are seeking. Because these drugs are injected directly into the eye, researchers aim to minimize application frequency while ensuring maximum effect. - Dear Accenture Stock Fans, Mark Your Calendars for October 1 - Dear Nike Stock Fans, Mark Your Calendars for Oct. 1 - Why It's Time to Load Up on ServiceNow Stock - Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. The results indicated that Zenkuda provided rapid vision and anatomic improvements during loading, followed by maintenance of optimal fluid control; with strict treat-to-dry retreatment criteria, more than half of patients reached a 24-week dosing interval. The AI-guided retreatment algorithm closely mirrors the zero-fluid-tolerance approach, which resulted in improved results. Kodiak Sciences' stock jumped on the DAYBREAK results release because it brings the pre-commercial company closer to the market. The company has planned to file a multi-indication biologics license application (BLA) in the fourth quarter of 2026, based on five positive Phase 3 studies across wet AMD, diabetic retinopathy, and retinal vein occlusion. Investors are likely sensing a commercial breakthrough, which could fuel further stock gains. Kodiak Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing next-generation therapies for chronic, high-prevalence retinal diseases. Headquartered in Palo Alto, California, the company leverages its proprietary Antibody Biopolymer Conjugate (ABC) platform to engineer longer-acting, more potent treatments targeting conditions like wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. Its lead candidate, tarcocimab tedromer (Zenkuda), is an anti-VEGF antibody biopolymer in late-stage trials, while KSI-501 and KSI-101 target broader disease biology, including inflammation, to potentially reduce injection frequency and improve outcomes. The company has a market capitalization of $5.73 billion. As the company inches closer to a blockbuster eye drug, Kodiak's stock has skyrocketed. Over the past 52 weeks, KOD stock has gained 532%. Basically, late-stage clinical data transformed it from a precommercial biotech into a near-term commercial candidate, driving the stock up a whopping 200% over the past five days. It reached an all-time high of $103.93 during this morning's trading but is down 4% from that level. It has a 14-day relative strength index (RSI) of 91.24, which is firmly in overbought territory, driven by the recent surge. The stock's price-to-book value ratio (on a forward basis) of 23.51x is significantly higher than the industry average of 3.36x. The company remains pre-revenue as it gears up for commercialization. Kodiak Sciences' second-quarter total expenses increased 20.4% year-over-year (YoY) to $66.84 million. However, most of this was made up of research and development expenses of $56.08 million, up 31.2% YoY. Net loss per share climbed by a modest 1.9% from the prior-year period to $1.05. Kodiak closed Q2 2026 with $125.90 million in cash and equivalents, which it expects will fund ongoing and planned operations into 2027. Wall Street analysts expect Kodiak Sciences' loss per share to decline by 14.7% YoY to $0.99 for the third quarter of fiscal 2026. The company's fiscal 2026 loss per share is expected to decrease by roughly 10% YOY to $3.89. However, next year, loss per share is projected to increase 5.1% annually to $4.09. After the pivotal Zenkuda study was released, analysts have raised their price target on KOD stock. Analysts at H.C. Wainwright maintained a "Buy" rating and raised the price target from $58 to $96. This followed the DAYBREAK study results. UBS analyst Michael Yee raised the firm's price target on Kodiak from $80 to $120 and kept a "Buy" rating on the shares, as the analyst believes the results strengthen the comeback thesis with non-inferior efficacy, clean safety, and differentiated durability. LifeSci Capital raised its price target on Kodiak from $85 to a Street-high $145 and kept an "Outperform" rating. The analyst told investors that aflibercept-like efficacy coupled with differentiated durability is "a best-case scenario outcome." Kodiak has become an extremely popular name on Wall Street in a short time, with analysts awarding it a consensus "Strong Buy" rating. Of the seven analysts rating KOD stock, a majority of five analysts have rated it a "Strong Buy," while two analysts gave it a "Hold" rating. The consensus price target of $87.28 represents an 11% downside from current levels. However, the Street-high price target of $145 indicates a 47% upside. On the date of publication, Anushka Dutta did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com

TARRYTOWN, N.Y., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2026 financial and operating results on Friday, October 30, 2026, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the 'Investors and Media' page of Regeneron's website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay and transcript of the conference call and webcast will be archived on the Company's website for at least 30 days. About Regeneron Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases. For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X. Contact Information: Investor Relations Ryan Crowe 914.847.8790 [email protected] | Corporate Communications Christina Chan 914.847.8827 [email protected]

A month has gone by since the last earnings report for Black Diamond (BDTX). Shares have added about 9.4% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Black Diamond due for a pullback? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent drivers for Black Diamond Therapeutics, Inc. before we dive into how investors and analysts have reacted as of late. Black Diamond reported second-quarter 2026 loss of 17 cents per share, narrower than the Zacks Consensus Estimate of a loss of 18 cents. The company had incurred a loss of 19 cents in the year-ago quarter. Black Diamond did not generate any revenues in the second quarter of 2026, consistent with the prior-year period. Research and development expenses declined 21% year over year to $7.4 million, primarily due to a decrease in spending related to the progression of the phase II NSCLC study of silevertinib, partially offset by increased spending on the phase II GBM study of the candidate. General and administrative expenses increased 14% to $4.7 million, primarily due to higher IP-related costs. Consequently, total operating expenses decreased to $12.1 million from $13.4 million reported in the prior-year quarter. Black Diamond ended the quarter with cash, cash equivalents and investments of $110.5 million compared with $118.3 million as of March 31, 2026. Management believes the current cash balance is sufficient to fund operations into the second half of 2028. Since the earnings release, investors have witnessed a downward trend in estimates review. The consensus estimate has shifted 40% due to these changes. Currently, Black Diamond has a nice Growth Score of B, however its Momentum Score is doing a bit better with an A. Charting a somewhat similar path, the stock was allocated a score of B on the value side, putting it in the second quintile for this investment strategy. Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in. Estimates have been broadly trending downward for the stock, and the magnitude of these revisions looks promising. Interestingly, Black Diamond has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months. Black Diamond is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Regeneron (REGN), a stock from the same industry, has gained 9.2%. The company reported its results for the quarter ended June 2026 more than a month ago. Regeneron reported revenues of $4.29 billion in the last reported quarter, representing a year-over-year change of +16.7%. EPS of $14.29 for the same period compares with $12.89 a year ago. Regeneron is expected to post earnings of $15.26 per share for the current quarter, representing a year-over-year change of +29%. Over the last 30 days, the Zacks Consensus Estimate remained unchanged. The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Regeneron. Also, the stock has a VGM Score of D. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Black Diamond Therapeutics, Inc. (BDTX) : Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Sound Shore Management, an investment management firm, has released its investor letter for the second quarter of 2026. The letter can be downloaded here. The Sound Shore Fund’s Investor Class (SSHFX) and Institutional Class (SSHVX) rose 10.48% and 10.58% in the second quarter of 2026, trailing the Russell 1000 Value Index’s 13.87% and the S&P 500’s 15.20% returns. Over three years, SSHFX and SSHVX posted annualized gains of 19.41% and 19.66%, outperforming the Russell Value (17.79%) but underperforming the S&P 500 (20.61%). The powerful rebound of stocks in the quarter was driven by strong performances in AI and semiconductor sectors, amidst easing inflation fears and a stable labor market. The portfolio also benefited from the AI wave in the second quarter. The ongoing AI revolution is creating significant investment opportunities in multiple sectors, and Sound Shore remains committed to long-term assessments of a company’s earning power, targeting stocks with durable management strategies. Also, check the fund’s top five holdings to see its best picks in 2026. In its Q2 2026 investor letter, Sound Shore Management highlighted Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biotechnology company that develops and commercializes medicines to treat various diseases. On August 26, 2026, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) closed at $814.79 per share, reflecting a market capitalization of $83.89 billion. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) posted a one‑month return of 10.35%, while its shares gained 40.58% over the past 52 weeks. Sound Shore Management stated the following regarding Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in its Q2 2026 investor letter: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 63 hedge fund portfolios held Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) at the end of the first quarter, which was 72 in the previous quarter. While we acknowledge the potential of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and shared the list of stocks surpassing earnings expectations. In addition, please check out our hedge fund investor letters Q2 2026 page for more investor letters from hedge funds and other leading investors. READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years. Disclosure: None. This article is originally published at Insider Monkey.

The FDA approved Pasatru, whose generic name is garetosmab, of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for adults with fibrodysplasia ossificans progressiva. FOP is an ultra-rare genetic disorder in which bone forms inside muscles, tendons, and ligaments, progressively restricting movement. In a 56-week Phase 3 trial involving 63 adults, the approved 3-milligram-per-kilogram dose reduced the number of new abnormal bone lesions by 94% compared with placebo. The decision completed an unusual clinical recovery. Regeneron paused an earlier study in 2020 after five patients died during its open-label portion, when all participants were receiving active treatment. The published analysis later considered a relationship to treatment unlikely, although causality could not be ruled out. For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), Pasatru is a regulatory and scientific victory whose earnings potential is constrained by an exceptionally small market. The company’s existing scale makes that limitation difficult to ignore. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) generated second-quarter revenue of $4.29 billion, up 17%, while company-defined non-GAAP diluted EPS reached $14.29. Global Dupixent sales, recorded by partner Sanofi, increased 38% to approximately $6 billion, and U.S. Eylea HD sales rose 52% to $596 million. Against those franchises, even a successful Pasatru launch would have limited influence on consolidated results. The approval demonstrates that Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) can recover a program after a major clinical setback. Following the 2020 dosing pause, the company worked with regulators to design a late-stage study that produced a statistically significant reduction in new bone lesions. Pasatru also validates research into Activin A, which activates the mutant ACVR1/ALK2 receptor and triggers abnormal bone formation in FOP. That platform value may matter more than initial sales. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) plans to begin a pediatric trial later in 2026, which could eventually expand the eligible population. The regulatory recovery may also strengthen confidence in the company’s ability to advance other rare-disease programs from internally discovered biology. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is entering an exceptionally small pharmaceutical market. Published prevalence estimates generally range from approximately one case per one million to one per two million people. Only approximately 800 to 900 known or confirmed cases have been identified globally, although additional patients may remain undiagnosed. Pasatru is currently approved only for adults, further narrowing its immediate market. Competition is already established. Ipsen’s oral therapy Sohonos received FDA approval in 2023 for adults and certain pediatric patients. Pasatru’s earlier safety history will also remain important during commercialization. Incyte and Mirum are jointly advancing zilurgisertib, while Ashibio is separately developing andecaliximab. Insider Monkey’s hedge fund database shows that 72 hedge funds held positions in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) at the end of the first quarter of 2026, compared with 75 funds at the end of the preceding quarter. These figures reflect holdings as of March 31, 2026, and do not capture later trades or investors’ reactions to the Pasatru approval for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Pasatru is unlikely to move near-term earnings materially for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), given the small diagnosed population and existing competition. Its greater value lies in rescuing a troubled program, validating the Activin A science and demonstrating that a major setback can still lead to an approved medicine. While we acknowledge the potential of REGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: ConocoPhillips (COP): Wall Street Sees More Upside Despite Leadership Shakeup and Here is Why Chevron (CVX) is a Favorite Among Hedge Funds Disclosure: None. This article is originally published at Insider Monkey.